20/21 December 2022
The European Medicines Agency (EMA) has started with the relocation to the Netherlands. The Dutch authorities have already officially handed over the temporary building, the Spark Building (Orlyplein 24, 1043 DP Amsterdam, The Netherlands).
EMA will leave its premises in London on 1 March 2019. From 4 to 8 March, the Agency will operate on the basis of extended teleworking. During this week only a small number of staff will be present in the new building. During the course of the following week (11-15 March) EMA staff will gradually move into the Spark Building.
It should be noted that from 4 March 2019 onwards the official address of EMA will be that of the future permanent building, located in Amsterdam Zuidas: European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands. However meetings and visits will take place at the Spark Building.
To ensure the continuation of the main activities EMA has implemented phase 4 of its business continuity plan (BCP). The focus will be on the authorisation, maintenance and supervision of medicines, ongoing Brexit preparedness/implementation activities and preparing for the implementation of the new veterinary legislation. Detailed information, also about certain other activities, can be found in the European Medicines Agency Brexit Preparedness Business Continuity Plan.
In April 2019, once the Agency has completed its move to the Spark Building in Amsterdam, the Agency will review which other activities from the multiannual work plan can be resumed in the second half of 2019.